Real-World Clinical Use and Outcomes of Telavancin for the Treatment of Bone and Joint Infections: Results from the Telavancin Observational Use Registry (TOUR™)

• Published in: Drugs - Real World Outcomes 2021-12, Vol.8 (4), p.509-518
• Main Authors: Sims, Charles R., Bressler, Adam M., Graham, Donald R., Lacy, Melinda K., Lombardi, David A., Castaneda-Ruiz, Bibiana
• Format: Article
• Language: English
• Subjects: Accountability; Antibiotics; Arthritis; Arthritis, Infectious; Clinical outcomes; Creatinine; Demographics; Dictionaries; Drug dosages; Drug therapy; Health insurance; Hispanic Americans; Infectious arthritis; Infectious bone diseases; Internal Medicine; International conferences; Medicine; Medicine & Public Health; NCT; NCT02288234; Original; Original Research Article; Pathogens; Patient outcomes; Patients; Penicillin; Pharmacology/Toxicology; Pharmacotherapy; Pneumonia; Prostheses; Staphylococcus infections
• ISSN: 2199-1154; 2198-9788
• DOI: 10.1007/s40801-021-00255-6

Background Additional antibiotic options are needed to treat bone and joint infections caused by penicillin-resistant Gram-positive pathogens. Objective This subanalysis of the Telavancin Observational Use Registry (TOUR™) aimed to record real-world telavancin usage patterns in patients with bone and joint infections treated with telavancin. Methods TOUR was a multicenter observational-use registry study conducted at 45 US sites between January 2015 and March 2017. Patient characteristics, infection type, infecting pathogen(s), previous treatment, telavancin dosing and duration, clinical response, and adverse event data were collected by retrospective medical chart reviews. As such, inclusion/exclusion criteria were limited, and any patient receiving at least one dose of telavancin at the discretion of the treating physician was eligible. Patients were assessed as either positive clinical response, failed treatment, or indeterminate outcome. Results Of the 1063 patients enrolled in TOUR, 27.4% (291/1063) were patients with bone and joint infections including osteomyelitis (with or without prosthetic material), acute septic arthritis, and prosthetic joint infections. Most of these patients had osteomyelitis without prosthetic material (191/291; 66.0%). Among patients assessed at the end of treatment, 211/268 (78.7%) achieved a positive clinical response, 26/268 (9.7%) failed treatment, and 31/268 (11.6%) had an indeterminate outcome. The most frequent pathogen was methicillin-resistant Staphylococcus aureus (110/291; 37.8%). The median (interquartile range [IQR as Q1, Q3]) telavancin dose was 750.0 mg (IQR, 750, 750 mg) or 8.2 mg/kg (IQR, 6.8, 9.7 mg/kg) administered for a median of 26 days (IQR, 12, 42 days). These assessments were recorded in the registry ≥ 30 days after the last dose of telavancin was administered. Conclusions Real-world data from the TOUR study show that clinicians are using once-daily telavancin with positive clinical outcomes for the treatment of bone and joint infections caused by Gram-positive pathogens. Clinical Trial Registration This trial was registered with ClinicalTrials.gov (NCT02288234) on 11 November, 2014.